ABILITY Neurotech receives MREC approval for ALS BCI clinical trial

ABILITY Neurotech has secured approval from the MREC NedMec in the Netherlands to initiate a chronic clinical trial of its fully implantable wireless BCI in patients with ALS. The clearance enables ABILITY Neurotech to move beyond intra-operative testing to long-term clinical investigation involving human participants. The study will implant the company’s BCI device in ALS patients, primarily assessing communication and speech restoration performance. Credit: Phalexaviles / Shutterstock.com. ABILITY Neurotech has secured approval from the Medical Research Ethics Committee (MREC) NedMec in the Netherlands to initiate a chronic clinical trial of its fully implantable wireless brain-computer interface (BCI) in patients with…

Source: Medical Device Network